Abciximab

Abciximab
Monoclonal antibody
Type Fab fragment
Source Chimeric (mouse/human)
Target CD41 7E3
Clinical data
Trade names Reopro
AHFS/Drugs.com monograph
Pregnancy
category
Routes of
administration		 IV
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Biological half-life <10 min–30 min
Identifiers
CAS Number 143653-53-6 YesY
ATC code B01AC13 (WHO)
DrugBank DB00054 YesY
ChemSpider none
UNII X85G7936GV YesY
KEGG D02778 YesY
ChEMBL CHEMBL1201584 N
Chemical data
Formula C2101H3229N551O673S15
Molar mass 47455.4 g/mol
 NYesY (what is this?)  (verify)

Abciximab (previously known as c7E3 Fab), a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[1]

While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug.(Tanguay, J.F., Eur Heart J 1999; 1 (suppl E): E27-E35 Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.[2]

Indications for use

Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement). The use of abciximab in this setting is associated with a decreased incidence of ischemic complications due to the procedure[3] and a decreased need for repeated coronary artery revascularization in the first month following the procedure.[4] Research also shows that this drug can be of use for patients with diabetes and chronic renal insufficiency. It is not the appropriate drug of choice if a patient is scheduled for an emergency surgery (i.e., heart surgery) because bleeding time may take about 12 hours to normalize.

Pharmacokinetics

Abciximab has a plasma half-life of about ten minutes, with a second phase half-life of about 30 minutes. However, its effects on platelet function can be seen for up to 48 hours after the infusion has been terminated, and low levels of glycoprotein IIb/IIIa receptor blockade are present for up to 15 days after the infusion is terminated. Abciximab does not require renal dose adjustment.

Side-effects

Many of the side effects of abciximab are due to its anti-platelet effects. This includes an increased risk of bleeding. The most common type of bleeding due to abciximab is gastrointestinal hemorrhage.

Thrombocytopenia is a rare but known serious risk. Abciximab-induced thrombocytopenia can typically be treated with transfusion of platelets. Abciximab induced thrombocytopenia is usually rapid occurring hours after administration but may occur up to 16 days later.[5] Transfusing platelets is the only known treatment and may have limited effectiveness as the drug may also bind to the new platelets. Platelet counts, which should average 150,000-400,000, can effectively drop to zero.

References

  1. ↑ "Abciximab". Drugs.com. Archived from the original on 20 April 2010. Retrieved 13 March 2010.
  2. ↑ "International Nonproprietary Names for Pharmaceutiical Substances" (PDF). WHO Drug Information 7 (4). 1993.
  3. ↑ "Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation.". The New England Journal of Medicine 330 (14): 956–61. 1994. doi:10.1056/NEJM199404073301402. PMID 8121459.
  4. ↑ Tcheng, J. E.; Kandzari, D. E.; Grines, C. L.; Cox, D. A.; Effron, M. B.; Garcia, E.; Griffin, J. J.; Guagliumi, G.; Stuckey, T.; Turco, M.; Fahy, M.; Lansky, A. J.; Mehran, R.; Stone, G. W.; Cadillac, I. (2003). "Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial". Circulation 108 (11): 1316–1323. doi:10.1161/01.CIR.0000087601.45803.86. PMID 12939213.
  5. ↑ Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration. Platelets. 2011;22(4):302-4. doi: 10.3109/09537104.2010.518324.

External links

This article is issued from Wikipedia - version of the Sunday, March 20, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.